IP Library Granted Patent US 9,885,032
Granted Patent B2
US 9,885,032 · App. 14/944,991 · Granted Feb 6, 2018

Multisort cell separation method

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,885,032
App. No.
14/944,991
Granted
Feb 6, 2018
Kind
B2
Abstract

The invention is directed to a method for enriching target cells from a sample of cells characterized by: a) contacting the sample with a cell aggregation agent and first magnetic particles having an iron content of 0.1 pg to 5000 pg, coupled to a first antigen recognizing moiety; and second magnetic particles having an iron content of 0.05 fg to 100 fg and coupled to a second antigen recognizing moiety to obtain mixture a) b) applying a first magnetic field gradient to the mixture a) thereby removing the cells bound to the first antigen recognizing moiety coupled to the first magnetic particles, to obtain a mixture b) and obtaining an agglomerate comprising the cells of mixture a) bound to the cell aggregation agent c) applying a second magnetic field gradient to the mixture b) thereby immobilizing the cells bound to the second antigen recognizing moiety d) recovering the immobilized cells from the second magnetic field gradient as target cells.

Claims (16)

1. A method for enriching target cells from a sample of blood comprising the steps:

a) contacting the sample with a cell aggregation agent and first magnetic particles having an iron content of 0.1 pg to 5000 pg, coupled to a first antigen recognizing moiety; and second magnetic particles having an iron content of 0.05 fg to 100 fg and coupled to a second antigen recognizing moiety to obtain mixture a);

b) applying a first magnetic field gradient to the mixture a) thereby removing the cells bound to the first antigen recognizing moiety coupled to the first magnetic particles, to obtain a mixture b) and obtaining an agglomerate comprising the cells of mixture a) bound to the cell aggregation agent;

c) applying a second magnetic field gradient to the mixture b) thereby immobilizing the cells bound to the second antigen recognizing moiety coupled to the second magnetic particles to obtain a mixture c); and

d) recovering the immobilized cells from the second magnetic field gradient as target cells;

wherein the first magnetic particles have a mean diameter of 1-5 μm and the second magnetic particles have a mean diameter of 10-250 nm.

2. The method according to claim 1 , wherein the agglomerate comprising the cells of the mixture a) bound to the cell aggregation agent are separated from mixture b).

3. The method according to claim 1 , wherein the second magnetic field gradient is higher than the first magnetic field gradient.

4. The method according to claim 1 , wherein the first and second magnetic field gradient is applied by subjecting mixture b) and mixture c) on ferromagnetic separation means into first and second magnetic field.

5. The method according to claim 1 , wherein the first magnetic particles have a coefficient of variation (cv) of diameter of less than 15%.

6. The method according to claim 1 , wherein the cell aggregation reagent is selected from the group consisting of fibrinogen, immunoglobulins, dextran, hydroxyethyl starch, polyvinyl pyrrolidone (PVP), methylcellulose and hydroxypropylmethylcellulose (HPMC).

7. The method according to claim 1 , wherein the first magnetic particles are coupled to a plurality of different first antigen recognizing moieties.

8. The method according to claim 1 , wherein the second magnetic particles are coupled to a plurality of different second antigen recognizing moieties.

9. The method according to claim 1 , wherein the first and/or second antigen recognizing moieties are antibodies against antigens selected from the group consisting of CD3, CD4, CD8, CD14, CD15, CD19, CD34, CD36, CD61, CD123, CD193, CD235a, IgE and TCRab.

10. The method according to claim 1 , wherein the sample of blood is a sample of whole blood, Buffy-Coat or peripheral blood.

11. The method according to claim 1 , wherein the cell aggregation agent aggregates erythrocytes.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 29, 2019
From: MILTENYI BIOTEC GMBH
To: MILTENYI BIOTEC B.V. & CO. KG
Reel/Frame 051443/0669 →